Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for XXXX .

@entity1 @entity137 @entity5 @entity409 @entity160 @entity157
PURPOSE: Data guiding selection of nonsurgical treatment of @entity157 ( @entity157 ) are lacking. We therefore compared outcomes between stereotactic body radiotherapy (SBRT) and radiofrequency ablation (RFA) for @entity157 . @entity1 AND METHODS: From 2004 to 2012, 224 @entity1 with inoperable, nonmetastatic @entity157 underwent RFA (n = 161) to 249 @entity5 or image-guided SBRT (n = 63) to 83 @entity5 . We applied inverse probability of treatment weighting to adjust for imbalances in treatment assignment. Freedom from local progression (FFLP) and @entity137 were retrospectively analyzed. RESULTS: RFA and SBRT groups were similar with respect to number of lesions treated per @entity1 , type of underlying @entity409 , and @entity5 size (median, 1.8 v 2.2 cm in maximum diameter; P = .14). However, the SBRT group had lower pretreatment @entity1 -Pugh scores (P = .003), higher pretreatment @entity160 levels (P = .04), and a greater number of prior liver-directed treatments (P < .001). One- and 2-year FFLP for @entity5 treated with RFA were 83.6% and 80.2% v 97.4% and 83.8% for SBRT. Increasing @entity5 size predicted for FFLP in @entity1 treated with RFA (hazard ratio [HR], 1.54 per cm; P = .006), but not with SBRT (HR, 1.21 per cm; P = .617). For @entity5 >=  2 cm, there was decreased FFLP for RFA compared with SBRT (HR, 3.35; P = .025). Acute grade 3+ complications occurred after 11% and 5% of RFA and SBRT treatments, respectively (P = .31). Overall survival 1 and 2 years after treatment was 70% and 53% after RFA and 74% and 46% after SBRT. CONCLUSION: Both RFA and SBRT are effective local treatment options for inoperable @entity157 . Although these data are retrospective, SBRT appears to be a reasonable first-line treatment of inoperable, larger @entity157 .
